Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
Holding KMDA?
Track your performance easily
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.74 - $8.00
Previous CloseN/A
Volume680.22K
Average Volume (3M)105.28K
Market Cap
$420.30M
Enterprise Value$922.83M
Total Cash (Recent Filing)$28.63M
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)26.2
Beta0.61
Next Earnings
Feb 12, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding57,485,615
10 Day Avg. Volume249,733
30 Day Avg. Volume105,281
Standard Deviation0.10
R-Squared0.27
Alpha-0.00833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap2.20
Enterprise Value/Revenue16.54
Enterprise Value/Gross Profit16.63
Enterprise Value/Ebitda298.94
Forecast
1Y Price Target
$11.00Price Target Upside53.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Kamada News
PremiumCompany Announcements
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations
PremiumCompany Announcements
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment
PremiumCompany Announcements
Kamada’s Strong Growth and Strategic Expansion in 2024
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKamada affirms their strong financial position for 2024 and 2025 with a projected increase in revenue and adjusted EBITDA.
Growth StrategyKamada's focus for 2025 is on securing new business development and M&A transactions, which could be a growth driver.
Regulatory ApprovalFDA agrees to previously proposed increased alpha value for the Phase 3 InnovAATe trial, which may decrease the required sample size and accelerate enrollment.
Bears Say
Enrollment ConcernsEnrollment in the AAT trial is expected to be a challenge despite additional sites being opened.
Partnership ChallengesKamada has yet to find a partner for the AAT program despite prior positive guidance from the European Medicines Agency.
Partnership ConcernsIt is concerning that a partnership for the AAT program has not yet materialized.
---
Ownership Overview
―
Insiders
2.06% Mutual Funds
4.87% Other Institutional Investors
91.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $4.74 and its highest was $8.00 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $420.30M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Feb 12, 2025 which is in 24 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Nov 13, 2024. The company reported $0.074 earnings per share for the quarter, beating the consensus estimate of $0.067 by $0.007.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada does not currently pay dividends.
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.05.
How many shares outstanding does Kamada have?
Kamada has 57,485,615 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.074 in its last earnings report, beating expectations of $0.067. Following the earnings report the stock price went down -3.828%.
Which hedge fund is a major shareholder of Kamada?
Among the largest hedge funds holding Kamada’s share is ARK Investment Management LLC. It holds Kamada’s shares valued at 0.
---
Kamada Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (53.63% Upside)
$11.00 (53.63% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 399.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.1%
Last 30 Days ▲ 37.7%
Last 30 Days ▲ 37.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.62%
12-Months-Change
Fundamentals
Return on Equity
6.37%
Trailing 12-Months
Asset Growth
4.20%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
---
KMDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue and EBITDA growth. The company showcased robust cash flow and strategic expansions in plasma collection and biosimilar products. However, there are ongoing challenges with FDA discussions and increased operating expenses. Overall, the highlights significantly outweigh the lowlights, indicating positive momentum.Read More>---
KMDA Stock 12 Month Forecast
Average Price Target
$11.00
▲(53.63% Upside)
Technical Analysis
Best Analysts Covering KMDA
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+15.17%
reiterated a buy rating 9 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +15.17% per trade.
---